Uliledlimab is an antibody designed to target CD73. The development pause will also allow I-Mab to allow data from an ongoing China-only randomised study conducted by its partner TJ Biopharma ...

Mab’s pipeline pivot had a sting in the tail. Weeks after shifting its focus, the biotech said Wednesday that it has reduced its workforce by around 27% in conjunction with the pipeline ...

Uliledlimab is the asset I-Mab has put on the back burner. The anti-CD73 antibody was the biotech’s lead candidate. But rather than advance into a phase 2 lung cancer trial, as I-Mab proposed in ...

A second asset is AB680 (quemliclustat), a small molecule CD73 antibody running a phase 3 trial in pancreatic cancer. There’s a third molecule, Etrumadenant, and two more, Casdatifan and ...

Innate Pharma (NASDAQ:IPHA – Get Free Report) and Agenus (NASDAQ:AGEN – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based ...

Uliledlimab (TJ004309) is an antibody designed to target CD73, the rate-limiting enzyme critical for adenosine-driven immunosuppression in the tumor microenvironment. I-Mab owns worldwide rights ...

不知道诸位还有印象吗？ 天境生物最早是以“别吃我”的CD47、腺苷通路的CD73作为发家点的。 但是继被艾伯维退货便销声匿迹的CD47抗体Lemzoparlimab后 ...